Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.44 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.44 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.44 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 4/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7405242 | 0.86 | HPGD (0.49) | HPGDCNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL6925911 | 0.84 | F2 (0.47) | F2ALDH1A1PRSS1 | |
| SCHEMBL3529974 | 0.82 | HPGD (0.67) | HPGDCNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL16795265 | 0.81 | HPGD (0.52) | HPGDCNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL17330349 | 0.81 | HPGD (0.47) | HPGDCNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL19376791 | 0.79 | HPGD (0.49) | HPGDCNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL17330402 | 0.79 | HPGD (0.46) | HPGDCNR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL6921462 | 0.79 | IDO1 (0.54) | HPGDKMT2AKDM4EALDH1A1 | |
| SCHEMBL6921461 | 0.78 | CYP1A2 (0.49) | CNR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL20563681 | 0.77 | HPGD (0.47) | HPGDCNR1PLAAT3PLAAT5PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099962-A1 | 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1697323-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005058826-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002057225-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | HPGD 2292/4885CNR1 915/4885PLAAT3 224/4885 |
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | HPGD 1078/4885CNR1 753/4885PLAAT3 1295/4885 |
| US-20070099962-A1 | 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin | F2, SERPINC1, SERPINE1 | HPGD 346/4885CNR1 2582/4885PLAAT3 1778/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | HPGD 2066/4885CNR1 1692/4885PLAAT3 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.